Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Picks Up The Pace Of Complete Response Letters Over June And July

Aug 05 2020

• By Bridget Silverman

'COMPLETED' red word as rubber stamp

Related Content

Palforzia Peanut Allergy Immunotherapy: Aimmune CEO On REMS Restrictions, Manufacturing

Mar 17 2020

Allergan Pulls EU Filing For Abicipar Pegol

Jul 20 2020

Keeping Track: US FDA Set For Speed With Approvals Of Inqovy, Rukobia, Dojolvy, Phesgo; Keytruda Loses Chance At AA In HCC

Jul 11 2020

Allergan Declines To Confirm Abicipar Pegol Fate

Jul 10 2020

Keeping Track Of US FDA Decisions: COVID-Induced Complete Response Letter For Contepo; Safety Sinks Abicipar Pegol; Approvals For Fintepla and Gimoti

Jun 29 2020

Intercept CRL Likely About OCA-Specific Concerns, Not NASH Endpoints

Jun 30 2020

Verrica’s Molluscum Product Set Back By FDA Usage Questions

Jul 14 2020

Intercept’s CRL Just Continues Upheaval In NASH

Jun 29 2020

Related Companies

Nabriva Therapeutics plc.

Heron Therapeutics, Inc.

Verrica Pharmaceuticals, Inc.

DBV Technologies

Trevena Inc.

Intercept Pharmaceuticals, Inc.

Genfit SA

Merck & Co., Inc.

Eisai Co., Ltd.

Genentech, Inc.

Nualtis

Gensco Pharma

Allergan plc

Molecular Partners AG

Additional Topics

United States Complete Response Letters Drug Review Drug Approval Standards Drug Safety Manufacturing Regulation US FDA Performance Tracker BioPharmaceutical

More from Complete Response Letters

More from Product Reviews

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window